AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
This article was originally published in The Pink Sheet Daily
Both AstraZeneca’s Tagrisso and Clovis’ rociletinib target metastatic EGFR T790M mutation-positive non-small cell lung cancer. Tagrisso was approved by FDA Nov. 13, while Clovis said its drug would be delayed because mature data showed fewer confirmed responses than earlier data.
Register for our free email digests: